Simon Read, Director at Dianthus Therapeutics, Inc. /DE/ (DNTH), sold 2,778 shares at $117.55 ($327K) on 2026-08-19, disclosed to the SEC on 2026-08-19.
Scheduled sale ($327k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| RARX | SELL | 2019-11-18 | $467K | — | Filing → |
| RARX | SELL | 2019-10-17 | $469K | — | Filing → |
| RARX | SELL | 2019-09-16 | $254K | — | Filing → |